AMENDMENTS TO THE CLAIMS

- 1. (Cancelled).
- 2. (Cancelled).
- 3. (Cancelled).
- 4. (Cancelled).
- 5. (Cancelled).
- 6. (Cancelled).
- 7. (Cancelled).
- 8. (Cancelled).
- 9. (Cancelled).
- 10. (Previously presented) A pharmaceutical composition comprising at least one compound according to any one of claims 20 to 24 and a pharmaceutically acceptable carrier material.
- 11. (Cancelled).
- 12. (Cancelled).
- 13. (Cancelled).
- 14. (Cancelled).
- 15. (Currently Amended) A method of preventing or treating a disorder or disease associated with orexin system dysfunctions, comprising administering to a subject in need thereof an effective amount of the <u>compund</u> compound according to any one of claims 20 to 24.
- 16. (Cancelled).
- 17. (Currently Amended) The method of claim 15, wherein said disorder or disease is an eating disorder or a sleep disorder.
- 18. (Cancelled).
- 19. (Currently Amended) The method of claim <u>17 25</u>, wherein said sleep disorder is selected from the group consisting of insomnias, narcolepsy and other disorders of excessive sleepiness, sleep-related dystonias, restless leg syndrome, sleep

apneas, jet-lag syndrome, shift-work syndrome, delayed or advanced sleep phase syndrome.

20. (Previously presented) The compound (2R)-2-{(1S)-6,7-dimethoxy-1-[2-(4-trifluoromethyl-phenyl)-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl}-*N*-methyl-2-phenyl-acetamide, structurally represented by formula (II):

in free or pharmaceutically acceptable salt form.

- 21. (Previously presented) The compound according to claim 20 which is (2R)-2-{(1S)-6,7-dimethoxy-1-[2-(4-trifluoromethyl-phenyl)-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl}-*N*-methyl-2-phenyl-acetamide in free base form.
- 22. (Previously presented) The compound according to claim 20 which is (2R)-2-{(1S)-6,7-dimethoxy-1-[2-(4-trifluoromethyl-phenyl)-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl}-*N*-methyl-2-phenyl-acetamide in pharmaceutically acceptable acid addition salt form;

wherein the acidic component of the acid addition salt is selected from the group consisting of hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, nitric acid, citric acid, formic acid, acetic acid, maleic acid, tartaric acid, fumaric acid, benzoic acid, pamoic acid, stearic acid, methanesulfonic acid, p-toluenesulfonic acid, salicylic acid, succinic acid, and trifluoroacetic acid.

- 23. (Previously presented) The compound according to claim 20 which is (2R)-2-{(1S)-6,7-dimethoxy-1-[2-(4-trifluoromethyl-phenyl)-ethyl]-3,4-dihydro-1*H*-isoquinolin-2-yl}-*N*-methyl-2-phenyl-acetamide hydrochloric acid salt.
- 24. (Cancelled).

- 25. (Cancelled).
- 26. (Currently Amended) The method of claim <u>17 25</u> wherein said sleep disorder is <u>an</u> insomnia.